OHR Pharmaceutical (NASDAQ:OHRP) posted its earnings results on Tuesday. The biotechnology company reported ($0.01) EPS for the quarter, Bloomberg Earnings reports.
OHRP traded up $0.01 during midday trading on Wednesday, reaching $0.16. The company had a trading volume of 1,900 shares, compared to its average volume of 1,275,578. OHR Pharmaceutical has a 12-month low of $0.15 and a 12-month high of $2.18.
Separately, ValuEngine raised shares of OHR Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.